We are live on ! Find out more
TENX icon

Tenax Therapeutics

25 hedge funds and large institutions have $13.1M invested in Tenax Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,849% more capital inflows, than outflows

Capital inflows: $4.24M | Capital outflows: $107K

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

14% more funds holding

Funds holding: 22 → 25 (+3)

10.59% more ownership

Funds ownership: 39.95% → 50.54% (+11%)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TENX Hedge Fund Activity: Q1 2025 in Review

25 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q1 2025, worth a combined $13.1M — up 56% from $8.43M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TENX positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $2.43M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $83.7K sold.

  • 25 institutional investors held Tenax Therapeutics (TENX) as of Q1 2025, up from 22 in Q4 2024.
  • Funds reported $13.1M of Tenax Therapeutics stock for Q1 2025, up 56% quarter-over-quarter.
  • 5 funds opened new Tenax Therapeutics positions in Q1 2025 and 2 closed out, a net change of +3 holders.
  • The largest Tenax Therapeutics buyer in Q1 2025 was RTW Investments, an estimated $2.43M added.
  • The largest Tenax Therapeutics seller in Q1 2025 was Two Sigma Investments, an estimated $83.7K sold.

Based on aggregated 13F filings for Q1 2025.